Lv51
1330 积分 2024-07-29 加入
Improved Risk Prediction Using a Refined European Guidelines Instrument in Pulmonary Arterial Hypertension Related to Congenital Heart Disease
2天前
已完结
Modulation of attention-deficit/hyperactivity disorder symptoms by short- and long-acting methylphenidate over the course of a day
5天前
已完结
An updated safety review of the current drugs for managing ADHD in children
11天前
已完结
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
11天前
已完结
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
11天前
已完结
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
11天前
已完结
Precision medicine for prostate cancer: An international perspective
12天前
已完结
Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer
14天前
已完结
Risk stratification in Eisenmenger syndrome
14天前
已完结
Raising the bar: triple therapy for pulmonary arterial hypertension associated with congenital heart disease
14天前
已关闭
皖公网安备34019202002308
